Similar virological response to half-dose of sofosbuvir and full-dose of daclatasvir therapy in patients with end-stage renal disease and acute hepatitis C
Objective The aim of this study was to observe the virological response to half-dose of sofosbuvir and full-dose of daclatasvir therapy in patients with end-stage renal disease(ESRD)and acute hepatitis C(AHC).Methods 49 patients with ESRD and AHC who underwent long-term hemodialysis in our hospital were enrolled between June 2020 and January 2022,and were randomly divided into observation(n=25)and control(n=24)groups,receiving half-dose of sofosbuvir and full-dose of daclatasvir or full-dose of sofosbuvir and full-dose of daclatasvir antiviral therapy for 12 weeks.Serum HCV RNA load was detected by RT-PCR,and the peripheral blood T lymphocyte subsets were detected by flow cytometry.Results The rapid virological response,end-of-treatment virological response,12-week sustained virological response(SVR12)and SVR24 in the observation group were 72.0%,96.0%,88.0%and 88.0%,not significantly different compared to 70.8%,95.8%,87.5%and 87.5%in the control group(P＞0.05);at the end of antiviral treatment,the estimated glomerular filtration ratein the observation group was(12.5±1.0)ml/min·1.73m2,much higher than[(9.0±1.0)ml/min·1.73m2,P＜0.05],while serum creatinine level was(448.5±11.7)μmol/L,much lower than[(477.4±12.6)μmol/L,P＜0.05]in the control;there were no significant differences as respect to the percentages of peripheral blood CD4+cells and CD8+cell as well as the CD4+/CD8+cell ratio between the two groups at the end of antiviral treatment or of the follow-up(P＞0.05);the incidence of untoward effects in the observation group during the antiviral therapy was 4.0%,much lower than 25.0%(P＜0.05)in the control group.Conclusion The modified half-dose of sofosbuvir and full-dose of daclatasvirin treating patients with ESRD and AHC is relatively efficacious,which might meet the request of antiviral therapy and the reduction of renal function injury,and needs multi-central verification.
国家科技期刊平台
NSTL
万方数据
维普
